SCHEDULE: Baslake Partners Discloses 1.9% Stake in LeonaBio

Baslake Partners, LP, along with its management entity and managing member, reported a passive 1.9% beneficial ownership stake in LeonaBio, Inc. as of December 31, 2025.

Summary

• Baslake Partners, LP, Baselake Management, LLC, and David Paolella (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 75,789 shares of Common Stock in LeonaBio, Inc., formerly known as Athira Pharma, Inc.
• This represents 1.9% of LeonaBio, Inc.'s outstanding Common Stock, based on 3,943,887 shares issued and outstanding as of November 5, 2025, as stated in the Issuer's 10-Q.
• The Reporting Persons disclaim beneficial ownership of the shares except to the extent of their pecuniary interest.
• The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a standard regulatory disclosure of a passive ownership stake and does not inherently convey positive or negative sentiment about the issuer's performance or prospects.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

This filing does not contain any forward-looking statements or guidance from LeonaBio, Inc. or the reporting entities regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by passive institutional investors who own more than 5% (or 1% for certain types of investors) of a company's stock, or in this case, an amendment to a previous filing. The 1.9% stake held by Baselake Partners is below the typical 5% threshold for initial 13G filings, suggesting this is an update to a previously reported position or a specific filing requirement for certain investor types. Such filings provide transparency into significant ownership positions but generally do not signal activist intent or major strategic shifts, especially given the certification of a passive investment purpose.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, albeit passive, institutional ownership stake in LeonaBio, Inc.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of a passive ownership stake and does not provide new information regarding the company's operational performance, financial health, or strategic direction. As such, it does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold their positions and evaluate the company based on its fundamental business performance and future disclosures.

Keywords

LeonaBio, Athira Pharma, Baslake Partners, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, Passive Stake